Anticipated costs on treatment of diabetes mellitus and its late complications in CR – preliminary study

Czech version

Authors: D. Bartášková ¹; R. Kožnarová ²; M. Kvapil ¹
Authors‘ workplace: Diabetologické centrum, Interní klinika 2. lékařské fakulty UK a FN Motol, Praha, přednosta doc. MUDr. Milan Kvapil, CSc. ¹; Centrum diabetologie IKEM, Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc. ²
Published in: Vnitř Lék 2005; 51(3): 304-313
Category: Original Contributions

Overview

The cost of one-year treatment of diabetes type 1 as well as diabetes type 2 in Czech Republic in 2002 is assessed in this article. An estimated cost of treatment of late diabetes complications is also presented. This is an inicial study, which aim is to make an economic model of diabetes treatment. Direct medical charges were estimated only. We have assessed cost of following diabetes treatment methods: diet, PAD,PAD + insulin, insulin. The cost of following late diabetes complications was estimated: diabetic retinopathy, diabetic nephropathy, diabetic food, amputation, blindness, transplantation, and hemodialysis. The cost of diabetic neuropathy and macrovascular complications has also been calculated. We have assumed that everybody is treated according to standards for diabetes treatment. The cost of each recommended medical discharge according to price scale was counted to the total cost. The databasis AISLP has been used for calculation the cost of medication. Number of patients with separate types of diabetes treatment and number of patients with diabetic complication has been founded in the Institute of medical information and statistics. One–year cost of diabetes treatment was evaluated at 8.35 miliards Czech Crown. One year cost of diabetic complications was evaluated at 5.164 miliards Czech Crowns.

Key words:
diabetes mellitus – finantial costingness – direct charges of late complications of diabetes – diabetes therapy

Sources

1. Bartoš V, Pelikánová T. Praktická diabetologie. Praha: Maxdorf 1996.

2. Bartoš V, Záhumenský E, Jirkovská A. Standardy péče o diabetickou nohu. Vnitř Lék 1996; 42(1): 54–56.

3. Bouček P, Teplan V. Standardy péče při diabetické nefropatii. Diabetol Metabol Endokr Výživa 1998; 2: 76–80.

4. Brunerová L, Anděl M. Kalkulace nákladů na léky, zdravotní materiál, některé vybrané léčebné výkony a služby sociální oblasti u pacientů se syndromem diabetické nohy. Vnitř Lék 2003; 49: 457–464.

5. CODE 2: Revealing the cost of type 2 Diabetes in Europe, Smith Kline Beecham Pharmauceuticals, 1999

6. Čechurová D et al. Ekonomický pohled na léčbu syndromu diabetická noha. Diabetol Metabol Endokr Výživa 2001; 4: 10.

7. Česká diabetologická společnost. Standardy péče o diabetes 2. typu. Prakt Lék 1997; 77: 401–403.

8. Fylling PC, Knighton D. Amputation in the diabetic population: Incidence, causes, cost, treatment and prevention. J Enterostom Ther 1989; 16: 247–255.

9. Herman W, Eastman RC. The effect of Treatment on the Direct Cost of Diabetes. Diab Care 1998; 21: 19–24.

10. Hollingworth W, Williams D. The Economics of Diabetes Care. In: Alberti K, Zimmet P, Defronzo R (eds). International textbook of diabetes mellitus. Chichester: John Wiley 1997: 1773–8.

11. Jirkovská A. Standardy dietní léčby diabetiků. Diabetol Metabol EndokVýživa 1999; 2(3): 149–154.

12. Klonoff DC, Schwartz DM. An Economic analysis of Interventions for Diabetes. Diab Care 2000; 23: 390–402.

13. Larsson J, Apelqvist J. Towards less amputation in diabetic patients: incidence, causes, cost, treatment, and prevention – a review. Acta Ortop Sca 1995; 66: 181–192.

14. Lepore M, Pampanelli S. Pharmakokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142–2148.

15. Nařízení vlády ČR č. 487/2000, úhrada zdravotní péče pro 1. pololetí 2001.

16. Owens DR, Bolli G. Insulin glargine. Lancet 2000; 356(9228): 443–445.

17. Palmer AL, Weiss C. The cost-effectiveness of different management strategies for type 1 diabetes: a Swiss perspective. Diabetologia 2000; 43: 13–26.

18. Péče o nemocné s onemocněním ledvin. Praha: ÚZIS ČR 2000.

19. Péče o nemocné s cukrovkou 2000. Praha: ÚZIS ČR 2001.

20. Perušičová J. Trendy soudobé diabetologie. Praha: Galén 2002; 6. vol: 57–95.

21. Perušičová J. Trendy soudobé diabetologie. Praha: Galén 2001; 5. vol: 51–83.

22. Raskin P. 16 week comparison of the Novel insulin analog glargine and NPH Human insulin used with insulin in patient with type 1 diabetes. Diab Care 2000; 11: 1666–1671.

23. Ratner PE. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diab Care 2000; 5: 639–643.

24. Riddle M. Timely addition of insulin to oral therapy for type 2 diabetes. Diab Care 2002; 2: 395–396.

25. Rosenstock J, Schwartz SL. Basal insulin therapy in type 2 diabetes. Diab Care 2001; 4: 631–636.

26. Rosenstock J, Park G. Basal insulin glargine versus NPH insulin in patient with type 1 diabetes on multiple daily insulin regiments. Diab Care 2000; 8: 1137–1142.

27. Russel LB, Gold MR. Úloha analýzy nákladové efektivity ve zdravotnictví a její vliv na zdraví. JAMA-CS 1997; 1: 41–46

28. Seznam zdravotních výkonů s bodovými hodnotami, 187/2000 Sb.

29. Schreiber Stephan: Improved Metabolic Control with a Favorable Weight Profile in Patients with Type 2. Diabetes Treated with Insulin Glargine in Clinical Practice, Diabetes 51, Sup.2,: A 114, June 2002

30. Siegel JE, Weinstein MC. Doporučení pro sestavování zprávy o analýze nákladové efektivity. JAMA–CS 1997; 3: 216–218.

31. Stern Z, Levy R. Analysis of direct cost of standard compared with intensive insulin treatment of insulin-dependent diabetes mellitus and cost of complications. Acta Diabetol 1996; 33: 48–52.

32. Syndrom diabetické nohy: Mezinárodní konsensus vypracovaný Mezinárodní pracovní skupinou pro syndrom diabetické nohy. Jirkovská A (red) Praha: Galén 2000: 23–26.

33. Szucs TD, Smala AM. Cost of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study. Fortschr Med 1998; 116(31): 34–38.

34. Škrha J. Standardy péče o diabetes mellitus typ 1. Diabetol Metabol Endokrin Výživa 1999; 2: 100–104.

35. The Diabetes Control and Complications Trial Research Group: The Effect of intensive Treatment of Diabetes on the Development and progression of long term Complications in insulin-dependent diabetes mellitus. The New England Journal of medicine 1993; 329: 977–986.

36. The Diabetes Control and Complications Trial Research Group: Resource Utilization and Cost of Care in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1468–1478.

37. The Diabetes Control and Complications Trial Research Group: Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276: 1409–1415.

38. UKPDS Group: Efficaty of atenolol and captopril in reducing risk of macro and microvascular complications in type 2 diabetes. UKPDS 39. Brit Med J 1998; 317: 713–720.

39. UKPDS Group: Intensive blood glucose control with SU or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS 33. Lancet 1998; 352(12): 837–853.

40. Vlček J et al. Farmakoepidemiologie, farmakoekonomika, farmakoinformatika – základy pro farmaceuty. Praha: Remedia 1999.

41. Weinstein MC. Doporučení panelu pro hodnocení nákladové efektivity ve zdravotnictví. JAMA–CS 1997; 2: 131–137.